Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus

International Reviews of Immunology

Volumn 24, Issue 5-6, 2005, Pages 327-339

  Eldor, Roy ^a   Cohen, Irun R ^b   Raz, Itamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Auto antigen; Diabetes mellitus type 1; Immune modulation; Innate immune system; Peptide 277

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; IMMUNOMODULATING AGENT; INSULIN; INTERLEUKIN 10; INTERLEUKIN 13; NICOTINAMIDE; OKT 3; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EXPERIMENTAL MOUSE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STREPTOZOCIN DIABETES; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT INDICATION;

ANIMALS; AUTOANTIGENS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 28744442825     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180500379697     Document Type: Review

References (85)

1. M.A. Atkinson and N.K. Maclaren, The pathogenesis of insulin-dependent diabetes mellitus, N. Engl. J. Med., 331(21): 1428-1436, 1994.
2. A.K. Foulis and J.A. Stewart, The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: Insulin content of islets, insulitis and associated changes in the exocrine acinar tissue, Diabetologia, 26(6): 456-461, 1984.
3. R. Tisch and H. McDevitt, Insulin-dependent diabetes mellitus, Cell, 85(3): 291-297, 1996.
4. M.L. King, A. Shaikh, D. Bidwell, A. Voller, and J.E. Banatvala, Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus, Lancet, 1(8339): 1397-9, 1983.
5. G. Eisenbarth and D. McCulloch, Pathogenesis of type 1 iabetes mellitus, In B.D. Rose (Ed.), UpToDate, Waltham, MA: UpToDate, 2005.
6. A. Jansen, M. van Hagen, and H.A. Drexhage, Defective maturation and function of antigen-presenting cells in type 1 diabetes, Lancet, 345(8948): 491-492, 1995.
7. K. Takahashi, M.C. Honeyman, and L.C. Harrison, Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes, J. Immunol., 161(5): 2629-2635, 1998.
8. S.A. Litherland, et al., Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus, J. Clin. Invest., 104(4): 515-523, 1999.
9. S.B. Wilson, S.C. Kent, K.T. Patton, T. Orban, R.A. Jackson, M. Exley, S. Porcelli, D.A. Schatz, M.A. Atkinson, S.P. Balk, J.L. Strominger, and D.A. Hafler, Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes, Nature, 391(6663): 177-181, 1998.
10. H. Beyan, L.R. Buckley, N. Yousaf, M. Londei, and R.D. Leslie, A role for innate immunity in type 1 diabetes? Diabetes Metab. Res. Rev., 19(2): 89-100, 2003.
11. P.F. Bougneres, P. Landais, C. Boisson, J.C. Carel, N. Frament, C. Boitard, J.L. Chaussain, and J.F. Bach, Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin, Diabetes, 39(10): 1264-1272, 1990.
12. R.B. Elliott, et al., Partial preservation of pancreatic beta-cell function in children with diabetes, Lancet, 2(8247): 631-632, 1981.
13. J. Silverstein, et al., Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus, N. Engl. J. Med., 319(10): 599-604, 1988.
14. G.S. Eisenbarth, et al., Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus, Diabetes Res., 2(6): 271-276, 1985.
15. K.J. Pennline, E. Roque-Gaffney, and M. Monahan, Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse, Clin. Immunol. Immunopathol., 71(2): 169-175, 1994.
16. M.J. Cameron, et al., IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function, J. Immunol., 159(10): 4686-4692, 1997.
17. M. Lee, et al., Prevention of autoimmune insulitis by delivery of interleukin-4 plasmid using a soluble and biodegradable polymeric carrier, Pharm. Res., 19(3): 246-249, 2002.
18. T. Hayashi, et al., Interleukin-4-expressing plasmid DNA inhibits reovirus type-2-triggered autoimmune insulitis in DBA/1 J suckling mice, Int. J. Exp. Pathol., 84(2): 101-106, 2003.
19. T. Wolfe, et al., Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: Addition of IL-4 increases safety, Eur. J. Immunol., 32(1): 113-121, 2002.
20. K.S. Ko, et al., Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice, Mol. Ther., 4(4): 313-316, 2001.
21. M. Feili-Hariri, et al., Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis, Hum. Gene. Ther., 14(1): 13-23, 2003.
22. D. Zipris and E. Karnieli, A single treatment with IL-4 via retrovirally transduced lymphocytes partially protects against diabetes in BioBreeding (BB) rats, Journal of the Pancreas, 3(3): 76-82, 2002.
23. K. Goudy, et al., Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice, Proc. Natl. Acad. Sci. U.S.A., 98(24): 13913-13918, 2001.
24. S.C. Wood, T.D. Rao, and A.B. Frey, Multidose streptozotocin induction of diabetes in BALB/cBy mice induces a T cell proliferation defect in thymocytes which is reversible by interleukin-4, Cell Immunol., 192(1): 1-12, 1999.
25. I.B. McInnes, et al., IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis, J. Immunol., 167(7): 4075-4082, 2001.
26. S. Schreiber, et al., Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group, Gastroenterology, 119(6): 1461-1472, 2000.
27. K.C. Herold and L., Taylor, Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? Immunol. Res., 28(2): 141-150, 2003.
28. L. Chatenoud, et al., Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice, Proc. Natl. Acad. Sci. U.S.A., 91(1): 123-127, 1994.
29. K.C. Herold, et al., Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N. Engl. J. Med., 346(22): 1692-1698, 2002.
30. B. Keymeulen, et al., Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes, N. Engl. J. Med., 352(25): 2598-2608, 2005.
31. E.L. Masteller, et al., Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes, J. Immunol., 171(10): 5587-5595, 2003.
32. S. Casares, et al., Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera, Nat. Immunol., 3(4): 383-391, 2002.
33. A. Kukreja, et al., Multiple immuno-regulatory defects in type-1 diabetes, J. Clin. Invest., 109(1): 131-140, 2002.
34. S. Hong, et al., The natural killer T-cell ligand alpha- galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice, Nat. Med., 7(9): 1052-1056, 2001.
35. B. Wang, Y.B. Geng, and C.R. Wang, CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes, J. Exp. Med., 194(3): 313-320, 2001.
36. S. Sharif, et al., Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes, Nat. Med., 7(9): 1057-1062, 2001.
37. Y.G. Chen, et al., Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes, J. Immunol., 174(3): 1196-1204, 2005.
38. A. Zanin-Zhorov, et al., T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors, FASEB J., 17(11): 1567-1569, 2003.
39. D. Elias, et al., Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein, Proc. Natl. Acad. Sci. U.S.A., 87(4): 1576-1580, 1990.
40. V. Ablamunits, D. Elias, and I.R. Cohen, The pathogenicity of islet-infiltrating lymphocytes in the non-obese diabetic (NOD) mouse, Clin. Exp. Immunol., 115(2): 260-267, 1999.
41. R. Abulafia-Lapid, et al., T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides, J. Autoimmun., 12(2): 121-129, 1999.
42. D. Elias, et al., Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein, Proc. Natl. Acad. Sci. U.S.A., 88(8): 3088-3091, 1991.
43. B. Reizis, D.M. Altmann, and I.R. Cohen, Biochemical characterization of the human diabetes-associated HLA-DQ8 allelic product: Similarity to the major histocompatibility complex class II I-A(g)7 protein of non-obese diabetic mice, Eur. J. Immunol., 27(10): 2478-2483, 1997.
44. B. Reizis, et al., The peptide-binding strategy of the MHC class II I-A molecules, Immunol. Today, 19(5): 212-216, 1998.
45. D. Elias and I.R. Cohen, The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin, Diabetes, 45(9): 1168-1172, 1996.
46. D. Elias, et al., Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens, Diabetes, 46(5): 758-764, 1997.
47. D. Elias and I.R. Cohen, Peptide therapy for diabetes in NOD mice, Lancet, 343(8899): 704-706, 1994.
48. O.S. Birk, et al., A role of Hsp60 in autoimmune diabetes: Analysis in a transgenic model, Proc. Natl. Acad. Sci. U.S.A., 93(3): 1032-1037, 1996.
49. I. Raz, et al., Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial, Lancet, 358(9295): 1749-1753, 2001.
50. A. Zanin-Zhorov, et al., Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: Effects on signaling, chemotaxis, and inflammation, J. Immunol., 175(1): 276-285, 2005.
51. O. Lider, et al., Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis, Science, 239(4836): 181-183, 1988.
52. A.W. Lohse, et al., Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells, Science, 244(4906): 820-822, 1989.
53. S. Sakaguchi, et al., Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance, Immunol. Rev., 182: 18-32, 2001.
54. H.L. Weiner, Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells, Immunol. Rev., 182: 207-214, 2001.
55. I.R. Cohen and D.B. Young, Autoimmunity, microbial immunity and the immunological homunculus, Immunol. Today, 12(4): 105-110, 1991.
56. I.R. Cohen, The cognitive paradigm and the immunological homunculus, Immunol. Today, 13(12): 490-494, 1992.
57. I.R. Cohen, Treatment of autoimmune disease: to activate or to deactivate? Chem. Immunol., 60: 150-160, 1995.
58. R. Tisch and H.O. McDevitt, Antigen-specific immunotherapy: Is it a real possibility to combat T-cell-mediated autoimmunity? Proc. Natl. Acad. Sci. U.S.A., 91(2): 437-438, 1994.
59. S.M. Lieberman and T.P. DiLorenzo, A comprehensive guide to antibody and T-cell responses in type 1 diabetes, Tissue Antigens, 62(5): 359-377, 2003.
60. A.G. Ziegler, et al., On the appearance of islet associated autoimmunity in offspring of diabetic mothers: A prospective study from birth, Diabetologia, 36(5): 402-408, 1993.
61. S.M. Lieberman, et al., Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes, Proc. Natl. Acad. Sci. U.S.A., 100(14): 8384-8388, 2003.
62. J.C. Hutton and G.S. Eisenbarth, A pancreatic beta-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes, Proc. Natl. Acad. Sci. U.S.A., 100(15): 8626-8628, 2003.
63. B. Han, et al., Prevention of diabetes by manipulation of anti-IGRP autoimmunity: High efficiency of a low-affinity peptide, Nat. Med., 11(6): 645-652, 2005.
64. R. Mukherjee, et al., Identification of CD4+ T cell-specific epitopes of islet-specific glucose-6-phosphatase catalytic subunit-related protein: a novel beta cell autoantigen in type 1 diabetes, J. Immunol., 174(9): 5306-5315, 2005.
65. S. Baekkeskov, et al., Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase, Nature, 347(6289): 151-156, 1990.
66. M. Nakayama, et al., Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice, Nature, 435(7039): 220-223, 2005.
67. A.G. Ziegler, et al., Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: The 2-year analysis of the German BABYDIAB Study, Diabetes, 48(3): 460-468, 1999.
68. S.C. Kent, et al., Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope, Nature, 435(7039): 224-228, 2005.
69. A. Muir, et al., Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription, J. Clin. Invest., 95(2): 628-634, 1995.
70. P. Pozzilli, The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention, Diabetes Metab. Res. Rev., 18(4): 257-259, 2002.
71. Diabetes Prevention Trial-Type 1 Diabetes Study Group, Effects of insulin in relatives of patients with type 1 diabetes mellitus, N. Engl. J. Med., 346(22): 1685-1691, 2002.
72. D.G. Alleva, et al., A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin, J. Clin. Invest., 107(2): 173-180, 2001.
73. D.L. Kaufman, et al., Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes, Nature, 366(6450): 69-72, 1993.
74. R. Tisch, B. Wang, and D.V. Serreze, Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent, J. Immunol., 163(3): 1178-1187, 1999.
75. R. Tisch, et al., Administering glutamic acid decarboxylase to NOD mice prevents diabetes, J. Autoimmun., 7(6): 845-850, 1994.
76. J.M. Pleau, et al., Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65), Clin. Immunol. Immunopathol., 76(1 Pt 1): 90-95, 1995.
77. J.F. Elliott, et al., Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice, Diabetes, 43(12): 1494-1499, 1994.
78. P. Sai, et al., Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524-543 reduces cyclophosphamide- accelerated diabetes, Clin. Exp. Immunol., 105(2): 330-337, 1996.
79. A.F. Li and A. Escher, Intradermal or oral delivery of GAD-encoding genetic vaccines suppresses type 1 diabetes, DNA Cell Biol., 22(4): 227-232, 2003.
80. B. Balasa, et al., Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection, Clin. Immunol., 99(2): 241-252, 2001.
81. H.S. Jun, et al., Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase, Diabetologia, 45(5): 668-676, 2002.
82. V. Menard, et al., Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice, Pharm. Res., 16(7): 1059-1066, 1999.
83. C.D. Agardh, et al., Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes, J. Diabetes Complications, 19(4): 238-246, 2005.
84. E.A. Gale, et al., European nicotinamide diabetes intervention trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes, Lancet, 363(9413): 925-931, 2004.
85. F.J. Quintana, et al., Functional immunomics: Microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes, Proc. Natl. Acad. Sci. U.S.A., 101(Suppl. 2): 14615-14621, 2004.